Get the Stockscreener App
100.95
0.01%
0.01
After Hours:
100.95
Lantheus Holdings Inc stock is traded at $100.95, with a volume of 1.30M.
It is up +0.01% in the last 24 hours and down -1.39% over the past month.
Lantheus Holdings Inc is a radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver patient outcomes. The Company classifies its products into Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Its products help healthcare professionals Find, Fight and Follow cancer and diseases and are used by physicians and technologists in clinical settings. The Company produces and markets its products in the United States, mainly to hospitals, independent imaging centers and government facilities, and sells outside the United States through direct and third-party distribution relationships and licensing arrangements in Europe, Canada, Australia, Asia-Pacific, Central America and South America.
See More
Previous Close:
$100.94
Open:
$100.95
24h Volume:
1.30M
Relative Volume:
1.02
Market Cap:
$6.59B
Revenue:
$1.54B
Net Income/Loss:
$233.56M
P/E Ratio:
29.98
EPS:
3.3669
Net Cash Flow:
$348.64M
1W Performance:
+0.00%
1M Performance:
-1.39%
6M Performance:
+45.50%
1Y Performance:
+85.33%
1-Day Range:
$100.85
$101.10
1-Week Range:
$100.58
$101.10
52-Week Range:
$49.67
$111.86
Lantheus Holdings Inc Stock (LNTH) Company Profile
Name
Lantheus Holdings Inc
Sector
Phone
978 671-8001
Address
331 TREBLE COVE ROAD, NORTH BILLERICA, MA
Compare LNTH vs TAK, TEVA, HLN, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LNTH
Lantheus Holdings Inc
|
100.95 | 6.57B | 1.54B | 233.56M | 348.64M | 3.3669 |
TAK
Takeda Pharmaceutical Co Adr
|
17.63 | 55.60B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
36.77 | 42.81B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.70 | 43.16B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
73.79 | 30.39B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
499.73 | 21.95B | 3.17B | 1.29B | 1.01B | 27.09 |
Lantheus Holdings Inc Stock (LNTH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-26-26 | Upgrade | William Blair | Mkt Perform → Outperform |
| Dec-12-25 | Upgrade | Truist | Hold → Buy |
| Oct-08-25 | Downgrade | Goldman | Buy → Neutral |
| Aug-12-25 | Downgrade | Truist | Buy → Hold |
| Dec-18-24 | Initiated | Goldman | Buy |
| Sep-03-24 | Initiated | Redburn Atlantic | Buy |
| Jul-10-24 | Reiterated | JMP Securities | Mkt Outperform |
| Dec-18-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Dec-04-23 | Initiated | TD Cowen | Outperform |
| Sep-29-23 | Initiated | William Blair | Outperform |
| Mar-08-23 | Initiated | JMP Securities | Mkt Outperform |
| Nov-30-22 | Initiated | SVB Leerink | Outperform |
| Oct-13-22 | Initiated | Mizuho | Buy |
| May-09-22 | Initiated | B. Riley Securities | Buy |
| Apr-13-22 | Initiated | Truist | Buy |
| Feb-01-21 | Initiated | SVB Leerink | Outperform |
| Jun-29-20 | Resumed | Jefferies | Buy |
| Aug-16-19 | Upgrade | CJS Securities | Market Perform → Market Outperform |
| Nov-02-17 | Upgrade | Wells Fargo | Market Perform → Outperform |
| Nov-08-16 | Reiterated | RBC Capital Mkts | Outperform |
| Sep-23-16 | Resumed | Credit Suisse | Neutral |
| Feb-24-16 | Reiterated | RBC Capital Mkts | Outperform |
| Dec-11-15 | Downgrade | Credit Suisse | Outperform → Neutral |
| Sep-30-15 | Downgrade | Wells Fargo | Outperform → Market Perform |
| Jul-20-15 | Initiated | Credit Suisse | Outperform |
| Jul-20-15 | Initiated | Jefferies | Buy |
| Jul-20-15 | Initiated | RBC Capital Mkts | Outperform |
| Jul-20-15 | Initiated | Robert W. Baird | Outperform |
| Jul-20-15 | Initiated | Wells Fargo | Outperform |
View All
Lantheus Holdings Inc Stock (LNTH) Latest News
FDA Approves Lantheus Imaging Drug for Alzheimer's Diagnostics - Sahm
Weekly Buzz: LNTH, CBLL Win FDA Nod; AURA Cuts Jobs; TDY Buys VREX; CGEM, DFTX Meet Trial Goals - RTTNews
US FDA approves Lantheus’ brain-imaging agent for Alzheimer’s assessment - KWSN
LNTH Looks 10.1% Overvalued on GF Value™ - GuruFocus
US FDA approves Lantheus' brain-imaging agent for Alzheimer's assessment - Reuters
Lantheus Wins FDA Approval for Alzheimer's Tau Imaging Agent Tauklarify - marketscreener.com
Lantheus tau PET imaging agent approved for Alzheimer’s (LNTH) - Seeking Alpha
FDA approves Lantheus’ tau imaging agent for Alzheimer’s disease - Investing.com
FDA approves Lantheus’ tau imaging agent for Alzheimer’s disease By Investing.com - Investing.com Australia
Lantheus Announces FDA Approval of TAUKLARIFY™ (Florquinitau F 18 Injection), an F18-Labeled Tau PET Imaging Agent for Alzheimer’s Disease - The Manila Times
FDA approves Lantheus brain scan to identify tau in Alzheimer’s - Stock Titan
Farallon group (LNTH) discloses 5.58M-share, 8.6% position in Lantheus - Stock Titan
Lantheus Holdings, Inc. (LNTH) Stock Forecasts - Yahoo Finance
Lantheus Holdings, Inc. (NASDAQ:LNTH) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
(LNTH) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Bowman Consulting Group Ltd. (Nasdaq – BWMN), Bowhead Specialty Holdings Inc. (NYSE – BOW), Lantheus Holdings Inc. (Nasdaq – LNTH), Safety Insuran - WBOC TV
Pacer Advisors Inc. Reduces Stock Holdings in Lantheus Holdings, Inc. $LNTH - MarketBeat
Lantheus Holdings: Why I Am Exiting Before The Merger Closes (NASDAQ:LNTH) - Seeking Alpha
Lantheus Holdings (LNTH): Investor Outlook on Strong Upside Potential and Robust Product Portfolio - DirectorsTalk Interviews
Empowered Funds LLC Takes Position in Lantheus Holdings, Inc. $LNTH - MarketBeat
Lantheus Holdings, Inc. $LNTH is Reinhart Partners LLC.'s 2nd Largest Position - MarketBeat
Assenagon Asset Management S.A. Raises Stock Holdings in Lantheus Holdings, Inc. $LNTH - MarketBeat
Lantheus (LNTH) Stock Shrugs Off Solid Profit As Margin Questions Linger - Sahm
Lantheus (NASDAQ:LNTH) Releases Earnings Results, Beats Expectations By $0.25 EPS - MarketBeat
Lantheus Holdings Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Lantheus Holdings, Inc.LNTH - Business Wire
Are DSGR, LNTH, ATKR Obtaining Fair Deals for their Shareholders? - Sahm
Form 8K Lantheus Holdings Inc For: 6 August By Investing.com - Investing.com South Africa
LNTH Looks 12.1% Overvalued on GF Value™ - GuruFocus
Lantheus Holdings, Inc. Suspends its Previously Issued Full Year 2026 Financial Guidance - marketscreener.com
Lantheus Holdings Inc earnings beat by $0.26, revenue topped estimates - Investing.com
Lantheus' Q2 Adjusted Earnings Fall, Revenue Rises - marketscreener.com
Lantheus Holdings, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Is Lantheus Holdings Inc (LNTH) Overvalued Despite Q2 Earnings M - GuruFocus
LNTH: Q2 2026 saw revenue growth, strategic acquisitions, and a pending merger with Curium - TradingView
Earnings Flash (LNTH) Lantheus Holdings, Inc. Reports Q2 Revenue $388.2M, vs. FactSet Est of $363.2M - marketscreener.com
Earnings Flash (LNTH) Lantheus Holdings, Inc. Posts Q2 Adjusted EPS $1.55 per Share, vs. FactSet Est of $1.30 - marketscreener.com
Lantheus Q2 revenue rises to $388.2 million - Quiver Quantitative
Lantheus Holdings: Q2 Earnings Snapshot - barchart.com
Lantheus (NASDAQ:LNTH) Reports Upbeat Q2 CY2026 - Yahoo Finance
Lantheus Reports Second Quarter 2026 Financial Results - marketscreener.com
Press Release: Lantheus Reports Second Quarter 2026 Financial Results - Moomoo
California State Teachers Retirement System Raises Stock Position in Lantheus Holdings, Inc. $LNTH - MarketBeat
Lantheus earnings in focus as investors weigh Curium merger deal By Investing.com - Investing.com
First Trust Advisors LP Purchases 44,713 Shares of Lantheus Holdings, Inc. $LNTH - MarketBeat
Earnings To Watch: Lantheus (LNTH) Reports Q2 Results Tomorrow - Barchart.com
54-Billion-Yuan Deal Officially Unveiled: Creating the Largest Merger & Acquisition in Radiopharmaceutical Sector History - 36Kr
France: Curium to merge with Lantheus in mega US$8bn radiopharmaceutical transaction - Investors in Healthcare
Lantheus to Be Acquired by Curium for $102.50 Cash Plus Up to $12.00 CVR - TradingView
Lantheus (LNTH) Agrees To Join Curium In Radiopharmaceuticals Deal - Yahoo Finance
Lantheus Holdings, Inc. Stock 12‑Month Price Target Cut to $110.17, Implies 11% Upside - TradingView
4 Firms Steer Curium's $8B Lantheus Take-Private Deal - Law360
Lantheus Holdings Inc Stock (LNTH) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.79%
5.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):